Effect of Sepimostat Mesilate on the Development of Glomerulonephritis in NZB/W F1 Mice



Hiroshi Watanabe*, Shuzo Sato, Rie Saito, Haruyo Iwadate, Hiroko Kobayashi, Hiromasa Ohira
Fukushima Medical University, Department of Gastroenterology and Rheumatology, School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Japan.


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 197
Abstract HTML Views: 140
PDF Downloads: 82
Total Views/Downloads: 419
Unique Statistics:

Full-Text HTML Views: 123
Abstract HTML Views: 101
PDF Downloads: 69
Total Views/Downloads: 293



© 2011 Watanabe et al;

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Fukushima Medical University, Department of Gastroenterology and Rheumatology, School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Japan; Tel: +81-24-547-1111; Fax: +81-24-547-2055; E-mail: chiehiro@fmu.ac.jp


Abstract

Objective:

To determine whether sepimostat mesilate inhibits activation of the complement pathways, and to evaluate the effectiveness of sepimostat mesilate on the development of glomerulonephritis in NZB/W F1 mice.

Methods:

We used the Wielisa complement functional kit to assess the inhibitory effect of sepimostat mesilate on activation of the complement pathways. Groups of 10 NZB/NZW mice (age 18-22 weeks) were given sepimostat mesilate (200 μg/dose) or glucose (control) five times a week for 5 weeks after onset of proteinuria.

Results:

Sepimostat mesilate dose-dependently inhibited the activity of all complement pathways. Administration of sepimostat mesilate after disease onset lowered the levels of blood urea nitrogen (243.2 ± 63.1 versus 120.9 ± 22.1 μg/dl; p<0.0001), C4d (0.244 ± 0.083 versus 0.153 ± 0.059 ng/dl; p=0.011), and delayed the development of proteinuria (0.822 ± 0.116 versus 0.470 ± 0.093 mg/mouse/day; p=0.046) at the end of treatment (22 weeks of age). After discontinuation of administration, blood urea nitrogen, C4d level, and proteinuria rapidly became elevated with no difference between the groups. Eventually, mortality was similar between treated and untreated mice.

Conclusions:

Sepimostat mesilate could be a therapeutic option for lupus nephritis.

Keywords: Sepimostat Mesilate, Systemic Lupus Erythematosus, NZB/W F1 Mouse.